Abstract

Hepatocyte growth factor (HGF) and its high affinity receptor, the tyrosine kinase Met, play a key role in embryo development and tumor invasion. Both HGF and Met are established targets for cancer therapy. However, the mechanism of their interaction is complex and remains elusive. HGF is secreted as a monomeric precursor (pro-HGF) that binds to but does not activate Met. Mature HGF is a α/β heterodimer containing a high affinity Met-binding site in the α-chain (HGF-α) and a low affinity Met-binding site in the β-chain (HGF-β). The extracellular portion of Met contains a semaphorin (Sema) domain, a cysteine-rich hinge (plexin-semaphorin-integrin), and four immunoglobulin-like domains (immunoglobulin-like regions in plexins and transcription factors (IPT) 1-4). HGF-β binds to Sema through a low affinity contact. The domain of Met responsible for high affinity binding to HGF-α has not been identified yet. Here we show that this long sought after binding site lies in the immunoglobulin-like region of Met and more precisely in IPT 3 and 4. We also show that IPT 3 and 4 are sufficient to transmit the signal for kinase activation to the cytoplasm, although the lack of Sema makes the receptor equally sensitive to mature HGF and pro-HGF. Finally, we provide evidence that soluble Met-derived proteins containing either the low affinity or high affinity HGF-binding site antagonize HGF-induced invasive growth both in vitro and in xenografts. These data suggest that the immunoglobulin-like region of Met cooperates with the Sema domain in binding to HGF and in controlling Met kinase activity. Although the IPT-HGF-α interaction provides binding strength, the Sema-HGF-β contact confers selective sensitivity to the active form of the ligand.

Highlights

  • The ␣-subunit is completely extracellular, whereas the ␤-subunit includes an extracellular region, a transmembrane domain, and a cytoplasmic tyrosine kinase domain

  • We report that the IPT region of Met, previously thought to merely function as a “stalk” presenting the Sema domain to the ligand [40], contains the high affinity binding site for the ␣-chain of Hepatocyte growth factor (HGF)

  • HGF is composed of a ␣- and a ␤-chain joined by a disulfide bridge in the mature protein

Read more

Summary

EXPERIMENTAL PROCEDURES

Protein Engineering—Soluble or transmembrane receptors and engineered ligands described in this work have been generated by standard PCR and genetic engineering techniques. Met phosphorylation analysis in lentiviral vectortransduced MDA-MB-435 cells was performed as previously described [32]. HGF Cross-linking and Met Activation Analysis—Lentiviral vector-transduced TOV-112D cells expressing Met⌬25–741 were subjected to surface biotinylation analysis using an ECLTM surface biotinylation module kit (Amersham Biosciences) according to the manufacturer’s instructions. The cell lysates were immunoprecipitated using antibodies directed against the C-terminal portion of Met [45], resolved by SDS-PAGE using a 3–10% polyacrylamide gradient, and analyzed by Western blotting using biotinylated anti-HGF antibodies (R & D). TOV-112D cells expressing Met⌬25–741 were deprived of serum growth factors for 3 days and stimulated with 1 nM HGF, uncleavable HGF, HGF NK1, or NK1-NK1 for 10 min. Transgene expression was determined on tumor sections by immunohistochemistry using anti-FLAG antibodies (Sigma). In all of the figures, the values are expressed as the means Ϯ standard deviation, and statistical significance is indicated by single (p Ͻ 0.05) or double (p Ͻ 0.01) asterisks

RESULTS
To test the inhibitory potential of
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call